Is Kymera (KYMR) the Best Performing American Stock in June 2026?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 10 Best Performing American Stocks in June 2026.

On June 30, 2026, BofA raised the firm’s price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) to $125 from $110 and kept a Buy rating on the shares. BofA adjusted its launch timing expectations after Kymera said enrollment in the phase 2b BROADEN trial evaluating KT-621 in atopic dermatitis was completed approximately 6 months ahead of schedule. BofA currently models $6B in nominal peak sales for KT-621 in AD.

On June 29, B. Riley raised the firm’s price target on Kymera Therapeutics to $155 from $117 and kept a Buy rating on the shares. B. Riley said the company unexpectedly completed BROADEN2 Phase 2b enrollment in moderate-to-severe atopic dermatitis six months early. The firm noted that Kymera moved the readout to year-end 2026 from mid-2027 and is advancing the planned Phase 3 initiation to mid-2027. B. Riley said it is a buyer of the stock on the “encouraging update,” calling KT-621 Kymera’s “single most important value driver.”

CVS Health Corporation (CVS) Shares Up Significantly After Jim Cramer Said He Was Looking For A Good Year

Pixabay/Public Domain

Also on June 29, Truist analyst Srikripa Devarakonda raised the firm’s price target on Kymera Therapeutics to $136 from $116 and kept a Buy rating on the shares. Devarakonda viewed Kymera positively following accelerated development timelines for KT-621, with clinician feedback pointing to strong interest in an oral therapy with Dupixent-like efficacy and high enthusiasm among dermatology key opinion leaders.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

While we acknowledge the risk and potential of KYMR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than KYMR and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1